FDA-cleared profile

SwiftSight-Brain

AIRS Medical Inc. · MRI · FDA-cleared (510(k))

Authorized purpose: Adjunctive brain MRI morphometry and lesion-quantification support for qualified healthcare professionals, including segmented overlays, volumetric measurements, normative percentiles and longitudinal comparison.

Clinical role
Automated quantitative and visualization aid; results are reviewed by a qualified medical professional and do not replace clinical judgment.
Images and patients
MRI · Brain
Key limitation
Keep in mind: The product is adjunctive and requires professional review. Automated quality control and protocol checks do not remove the need to verify image quality, acquisition compatibility and clinical context.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Adjunctive brain MRI morphometry and lesion-quantification support for qualified healthcare professionals, including segmented overlays, volumetric measurements, normative percentiles and longitudinal comparison.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain Input: DICOM brain MRI with specified 3D T1 and T2 FLAIR acquisitions and protocols; supported scanners and acquisition requirements define the cleared processing scope.
  • Who uses it?Intended users: Radiologists, neurologists and other qualified healthcare professionals interpreting brain MRI.
  • What does the software produce?Output: Segmented color overlays, labels and volumes, age- and sex-matched reference percentiles, prior-study comparison, morphometric reports, and PACS/DICOM and PDF-style report outputs described in the submission.
  • What is its most important limitation?Key limitation: The product is adjunctive and requires professional review. Automated quality control and protocol checks do not remove the need to verify image quality, acquisition compatibility and clinical context.

Clinical takeaway. Clinical role: Adjunctive brain MRI morphometry and lesion-quantification support for qualified healthcare professionals, including segmented overlays, volumetric measurements, normative percentiles and longitudinal comparison.

Evidence takeaway. Evidence from the reviewed source record: The FDA summary reports 3D T1 accuracy and reproducibility testing across scanners and countries, with Dice thresholds above 0.80 for major subcortical structures and above 0.75 for cortical structures and mean volume differences within 5%. T2 FLAIR testing reported lesion Dice above 0.80 and mean absolute lesion-volume difference below 0.25 cc.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Adjunctive brain MRI morphometry and lesion-quantification support for qualified healthcare professionals, including segmented overlays, volumetric measurements, normative percentiles and longitudinal comparison.
  • Exact FDA submission
  • Checked 2026-09-07
Workflow role
Automated quantitative and visualization aid; results are reviewed by a qualified medical professional and do not replace clinical judgment.
  • Exact FDA submission
  • Checked 2026-09-07
Required input
DICOM brain MRI with specified 3D T1 and T2 FLAIR acquisitions and protocols; supported scanners and acquisition requirements define the cleared processing scope.
  • Exact FDA submission
  • Checked 2026-09-07
Output and clinician action
Segmented color overlays, labels and volumes, age- and sex-matched reference percentiles, prior-study comparison, morphometric reports, and PACS/DICOM and PDF-style report outputs described in the submission.
  • Exact FDA submission
  • Checked 2026-09-07
Care setting
Healthcare neuroimaging services using supported brain MRI protocols.
  • Exact FDA submission
  • Checked 2026-09-07
Intended users
Radiologists, neurologists and other qualified healthcare professionals interpreting brain MRI.
  • Exact FDA submission
  • Checked 2026-09-07
Limitations
The product is adjunctive and requires professional review. Automated quality control and protocol checks do not remove the need to verify image quality, acquisition compatibility and clinical context.
  • Exact FDA submission
  • Checked 2026-09-07
Evidence summary
The FDA summary reports 3D T1 accuracy and reproducibility testing across scanners and countries, with Dice thresholds above 0.80 for major subcortical structures and above 0.75 for cortical structures and mean volume differences within 5%. T2 FLAIR testing reported lesion Dice above 0.80 and mean absolute lesion-volume difference below 0.25 cc.
  • Exact FDA submission
  • Checked 2026-09-07

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The FDA summary reports 3D T1 accuracy and reproducibility testing across scanners and countries, with Dice thresholds above 0.80 for major subcortical structures and above 0.75 for cortical structures and mean volume differences within 5%. T2 FLAIR testing reported lesion Dice above 0.80 and mean absolute lesion-volume difference below 0.25 cc.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-07

The cleared endpoints are segmentation, volume and reproducibility measures rather than disease-detection sensitivity.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-07

The cleared endpoints are segmentation, volume and reproducibility measures rather than disease-detection specificity.

3D T1 major subcortical Dice threshold

0.8 Dice coefficient, minimum reported threshold

  • EndpointSegmentation overlap
  • Population72-case 3D T1 accuracy and reproducibility evaluation across Philips, Siemens and GE scanners
  • Tested versionSS25-BR-CL configuration submitted in K251483

3D T1 cortical Dice threshold

0.75 Dice coefficient, minimum reported threshold

  • EndpointSegmentation overlap
  • Population72-case 3D T1 accuracy and reproducibility evaluation across Philips, Siemens and GE scanners
  • Tested versionSS25-BR-CL configuration submitted in K251483

3D T1 mean volume-difference threshold

5 percent absolute difference, maximum reported threshold

  • EndpointMean volume difference
  • Population72-case 3D T1 accuracy and reproducibility evaluation
  • Tested versionSS25-BR-CL configuration submitted in K251483

T2 FLAIR lesion Dice threshold

0.8 Dice coefficient, minimum reported threshold

  • EndpointLesion segmentation overlap
  • Population160-case T2 FLAIR accuracy evaluation and 85-case reproducibility evaluation
  • Tested versionSS25-BR-CL configuration submitted in K251483

T2 FLAIR mean absolute lesion-volume threshold

0.25 cc, maximum reported threshold

  • EndpointMean absolute lesion-volume difference
  • Population160-case T2 FLAIR accuracy evaluation
  • Tested versionSS25-BR-CL configuration submitted in K251483

SwiftSight-Brain 3D T1 accuracy and reproducibility

  • DesignAccuracy and reproducibility evaluation across scanner manufacturers, field strengths, countries and adult age decades
  • Population3D T1 brain MRI: 72 accuracy/reproducibility cases; scanner subsets included Philips 54, Siemens 53 and GE 37 across the reported evaluations
  • Scopeexact submission
  • Tested versionSS25-BR-CL configuration submitted in K251483
  • Samplen=72
  • IndependenceSponsor or vendor study

K251483

FDA reports Dice >0.80 for major subcortical and >0.75 for cortical structures and mean volume differences <=5%.

SwiftSight-Brain T2 FLAIR lesion accuracy and reproducibility

  • DesignAccuracy and reproducibility evaluation for brain lesion segmentation and volume
  • PopulationT2 FLAIR brain MRI with 160 accuracy cases and 85 reproducibility cases across vendors and countries
  • Scopeexact submission
  • Tested versionSS25-BR-CL configuration submitted in K251483
  • Samplen=160
  • IndependenceSponsor or vendor study

K251483

FDA reports lesion Dice >0.80 and mean absolute lesion-volume difference <0.25 cc.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-07

The downloaded exact-ID recall packet contained zero records; this limited result does not establish absence of recall or safety information.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM brain MRI with specified 3D T1 and T2 FLAIR acquisitions and protocols; supported scanners and acquisition requirements define the cleared processing scope.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-07 · FDA 510(k) K251483: SwiftSight-Brain

  2. Routing

    Source context, not route validation: Processes DICOM brain MRI and returns segmented/quantitative results for PACS or report workflow; the exact site routing and viewer configuration require confirmation.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · FDA 510(k) K251483: SwiftSight-Brain

  3. AI processing

    Source context, not route validation: Software processing service with automated QC and DICOM/PACS/report outputs; the public FDA summary does not establish the customer's hosting model.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-07 · FDA 510(k) K251483: SwiftSight-Brain

  4. Returned objects

    Source context, not route validation: Segmented color overlays, labels and volumes, age- and sex-matched reference percentiles, prior-study comparison, morphometric reports, and PACS/DICOM and PDF-style report outputs described in the submission.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-07 · FDA 510(k) K251483: SwiftSight-Brain

  5. Viewer/worklist/report

    Unresolved route: Segmented color overlays, labels and volumes, age- and sex-matched reference percentiles, prior-study comparison, morphometric reports, and PACS/DICOM and PDF-style report outputs described in the submission.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-07 · FDA 510(k) K251483: SwiftSight-Brain

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Software processing service with automated QC and DICOM/PACS/report outputs; the public FDA summary does not establish the customer's hosting model.
  • Exact FDA submission
  • Checked 2026-09-07
Integration
Processes DICOM brain MRI and returns segmented/quantitative results for PACS or report workflow; the exact site routing and viewer configuration require confirmation.
  • Exact FDA submission
  • Checked 2026-09-07
Security
AIRS Medical announced it obtained ISO/IEC 27001 (information security management), ISO/IEC 27017 (cloud information security), and ISO/IEC 27018 (cloud personal information protection) certifications from Bureau Veritas, scoped to the company's cloud-based services.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement (Korean-language press release on the owning domain, 2023-09-25); certificates not read. Certification scope is the company's cloud-based services. Exact-release scope is not established.

DICOM/PACS and report outputs

The cleared workflow returns segmented overlays, quantitative reports and DICOM/PACS-compatible results for professional review.

exact submission · checked 2026-09-07

Institution-level longitudinal configuration

AIRS Medical's current SwiftSight-Brain release notes describe automatic prior-study detection, a longitudinal badge and service-engineer configuration.

product family · checked 2026-09-06

Current family release behavior is not asserted as the exact K251483 release.

Family data-handling controls

Current SwiftSight-Brain release notes describe configurable retention/auto-purge, MFA and removal of patient names from processing history or generated reports.

product family · checked 2026-09-06

These statements do not establish a formal security certification or exact K251483 contract.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K251483
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-09-23
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-07Last searched
23Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored candidate metadata was screened; no PubMed or trial IDs were returned for this submission. This is not a full-paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, vendor faq, vendor release note, stored candidate metadata, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-07 - Exact FDA submission

    No public price or quote for SS25-BR-CL was reviewed.

  • Pricing model: Not verified - checked 2026-09-07 - Exact FDA submission

    License, per-study, subscription and implementation terms were not established.

  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "SwiftMR AIRS Medical reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-10-27 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

11 sources - 3 history items

Source ledger

  1. FDA 510(k) K251483: SwiftSight-Brain

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: identity, purpose, clinicalUse, modality, anatomy, workflowRole, intendedUsers, careSetting, input, output, limitations, integration, deployment, evidenceMetrics, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. SwiftSight-Brain model card (K251483)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. AIRS Medical FAQ: SwiftMR & SwiftSight Questions

    AIRS Medical - Accessed 2026-09-06

    Scope: productFamilyContext, clinicalUse, implementationCapabilities

  8. SS25-BR-CL v1.0.1.0

    AIRS Medical - Accessed 2026-09-06

    Scope: implementationCapabilities, security

  9. SS25-BR-CL v1.0.4.0

    AIRS Medical - Accessed 2026-09-06

    Scope: implementationCapabilities, security

  10. AIRS Medical SwiftMR Information Security white paper summary

    AIRS Medical - Accessed 2026-10-25

    Scope: security

  11. AIRS Medical: ISO/IEC 27001/27017/27018 Certification Announcement

    AIRS Medical - Published 2023-09-25 - Accessed 2026-10-27

    Scope: security

Research history

  1. K251483 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K261405

ANDI 2.2

Imeka Solutions, Inc.

Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.

Modality
MRI
Anatomy
Brain
Decision
2026-05-28
FDA-cleared K260032

Morph

BeauBrain Healthcare, Inc.

Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.

Modality
MRI
Anatomy
Brain
Decision
2026-05-13
FDA-cleared K253057

AI-Rad Companion Brain MR

Siemens Healthcare GmbH

Authorized purpose: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.

Modality
MRI
Anatomy
Brain
Decision
2026-01-22
FDA-cleared K252298

ANDI 2.0

Imeka Solutions, Inc.

Authorized purpose: Adjunctive quantitative brain MRI analysis that compares patient measures with normative and longitudinal references; a physician reviews all results and makes the clinical decision.

Modality
MRI
Anatomy
Brain
Decision
2025-10-22

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history